ABVX

Abivax

ABVX

Market cap $6.49B

Overview Fund Activity

85.87 USD

+1.86

2.21%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

86.30

+0.43

0.5%

1 day

2.21%

5 days

-3.95%

1 month

21.91%

3 months

1,177.83%

6 months

1,331.17%

Year to date

1,077.91%

1 year

648%

5 years

934.58%

10 years

934.58%

About: Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Employees: 69

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

45% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 11

25% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 5 (+1) [Q2]

18% more capital invested

Capital invested by funds: $199M [Q1] → $235M (+$36.1M) [Q2]

1.76% less ownership

Funds ownership: 50.08% [Q1] → 48.33% (-1.76%) [Q2]

7% less funds holding

Funds holding: 46 [Q1] → 43 (-3) [Q2]

33% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 9

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$70

18% downside

Avg. target

$99

15% upside

High target

$112

30% upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

Morgan Stanley Judah Frommer	$101	Overweight Maintained	12 Sep 2025
BTIG Julian Harrison	$112	Buy Reiterated	9 Sep 2025
Piper Sandler Allison Bratzel	$112	Overweight Maintained	29 Jul 2025
Piper Sandler Christopher Raymond	$70	Overweight Maintained	23 Jul 2025
LifeSci Capital Sam Slutsky	$101	Outperform Maintained	23 Jul 2025
Guggenheim Yatin Suneja	$101	Buy Maintained	23 Jul 2025
JMP Securities Jason Butler	$95	Market Outperform Maintained	23 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about ABVX published over the past 30 days

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review PARIS, France, September 12, 2025, 5:45 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today that following the annual review of the Euronext Paris indices on September 11, 2025, the Scientific Council of the Indices has decided to admit Abivax to the CAC Mid 60 and SBF 120 indices.

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

Abivax Presents First Half 2025 Financial Results

Abivax Presents First Half 2025 Financial Results PARIS, France, September 8, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial information for the six months ended June 30, 2025.

Abivax Presents First Half 2025 Financial Results

How Hedge Funds Won Big on an Obscure Drugmaker

Results of a Paris company's late-stage drug trial helped turn things around for healthcare-focused funds, which struggled in the first half of the year.

How Hedge Funds Won Big on an Obscure Drugmaker

2 Logical Mid-Cap Biotech Buyout Targets

There have been some significant acquisitions in the mid-cap biotech space over the past couple of months. In today's column, I highlight two mid-cap biotech names that should have bright futures on their own, but would make logical buyout candidates: Abivax Société Anonyme and MoonLake Immunotherapeutics. Both have late-stage assets targeting large markets, and both companies should file for their first FDA approvals in 2026.

2 Logical Mid-Cap Biotech Buyout Targets

The Motley Fool

This Stock Is Up by 800% This Year -- but Is It a Buy?

If you had invested money in Abivax (ABVX 0.73%) at the beginning of the year, you would be sitting pretty right now. The French biotech's shares recently skyrocketed and are up more than 800% year to date.

This Stock Is Up by 800% This Year -- but Is It a Buy?

Abivax Announces Closing of $747.5 Million Public Offering

Abivax Announces Closing of $747.5 Million Public Offering PARIS, France, July 28, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces the closing of its previously announced underwritten public offering of 11,679,400 American Depositary Shares (“ADSs”), each representing one ordinary share, €0.01 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “Offering”), which includes the full exercise of the underwriters' option to purchase additional ADSs (the “Underwriters' Option”).

Abivax Announces Closing of $747.5 Million Public Offering

Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Abivax: Positive Obefazimod Induction Data Leads To Next 44-Week Maintenance Trial Catalyst

Abivax shares surged 500% after positive phase 3 results for obefazimod in moderate-to-severe ulcerative colitis, achieving significant clinical remission at 8 weeks induction period. Both ABTECT-1 and ABTECT-2 studies showed statistically significant results, supporting obefazimod's differentiated safety and efficacy profile as a first-in-class oral miR-124 enhancer. The next major catalyst is the 44-week maintenance trial data, expected in Q2 2026, which could enable a New Drug Application filing of obefazimod in H2 2026.

Abivax: Positive Obefazimod Induction Data Leads To Next 44-Week Maintenance Trial Catalyst

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 02:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from 3:30 p.m.

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares PARIS, France, July 24, 2025 – 2:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces the pricing of its previously announced underwritten public offering of 10,156,000 American Depositary Shares (“ADSs”), each representing one ordinary share, €0.01 nominal value per share (each an “Ordinary Share”), of the Company, in the United States at an offering price of $64.00 per ADS (the “Offering”).

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

See News Rankings

Charts implemented using Lightweight Charts™